The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder (MDD), the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped......
[Full Story]